Paul J. Sekhri
Paul J. Sekhri's purchase track record
Paul J. Sekhri has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/3/2026 | APMD | $200K | pending | pending | — |
| 11/15/2024 | VTVT | $84K | +24.7% | +20.9% | +1.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Apnimed to Present Five Abstracts at CHEST 2026. Apnimed announced it will present five abstracts, including two late-breaking studies, at the CHEST 2026 conference. This highlights the company's ongoing research activity and clinical data generation. The stock currently trades well below its 52-week high, with an average analyst target of $50.33.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
VTVT Completes Phase 3 Cadisegliatin Trial Enrollment. vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.
Transaction History
| VEEV | ▲ Buy | Option Exercise | 460 | $0 | 9/1/2026 | View on chart |
| APMD | ▲ Buy | Open Market | 12,500 | $200K | 8/3/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 253 | $0 | 6/1/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 253 | $0 | 3/1/2026 | View on chart |
| VEEV | ▼ Sell | Gift | 2,491 | $0 | 12/2/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 254 | $0 | 12/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 253 | $0 | 9/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 329 | $0 | 6/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 328 | $0 | 3/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 329 | $0 | 12/1/2024 | View on chart |
| VTVT | ▲ Buy | Open Market | 1,844 | $31K | 11/18/2024 | View on chart |
| VTVT | ▲ Buy | Open Market | 1,378 | $23K | 11/15/2024 | View on chart |
| VTVT | ▲ Buy | Open Market | 1,778 | $30K | 11/15/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 329 | $0 | 9/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 290 | $0 | 6/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 290 | $0 | 3/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 290 | $0 | 12/1/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,500 | $562K | 9/11/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 290 | $0 | 9/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 313 | $0 | 6/1/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,540 | $462K | 3/3/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 118 | $22K | 3/3/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 313 | $0 | 3/1/2023 | View on chart |
| VEEV | ▼ Sell | Gift | 702 | $0 | 12/16/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 313 | $0 | 12/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 313 | $0 | 9/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 189 | $0 | 6/1/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 11,000 | $2.4M | 3/31/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 189 | $0 | 3/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 189 | $0 | 12/1/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 189 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.